Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H18N4O4 |
| Molecular Weight | 330.3385 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)C1=CC=C(NC(=O)CCC(=O)N[C@@H](CC(O)=O)C#C)C=C1
InChI
InChIKey=OUZLOTRPGMFLPN-LLVKDONJSA-N
InChI=1S/C16H18N4O4/c1-2-11(9-15(23)24)19-13(21)7-8-14(22)20-12-5-3-10(4-6-12)16(17)18/h1,3-6,11H,7-9H2,(H3,17,18)(H,19,21)(H,20,22)(H,23,24)/t11-/m1/s1
| Molecular Formula | C16H18N4O4 |
| Molecular Weight | 330.3385 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Xemilofiban [SC 54684, SC 54684A (HCl), xemlofiban], an orally active antiplatelet agent, is a glycoprotein IIb/IIIa receptor antagonist. This drug was in a phase III clinical trial in the US and Europe for the treatment of thrombosis in patients with unstable angina pectoris and acute myocardial infarction undergoing angioplasty. Because of insufficient evidence of efficacy and concerns about safety over this long of a period of treatment, these trials didn’t get the market approval. In Japan, Sankyo discontinued the development of xemilofiban for thrombosis at phase II following Searle's decision to drop the project.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. | 2002 Dec |
|
| Xemilofiban: SC 54684A, xemlofiban. | 2003 |
|
| Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). | 2008 Nov 1 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:35:54 GMT 2023
by
admin
on
Sat Dec 16 08:35:54 GMT 2023
|
| Record UNII |
TN585Y92BI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9862322
Created by
admin on Sat Dec 16 08:35:54 GMT 2023 , Edited by admin on Sat Dec 16 08:35:54 GMT 2023
|
PRIMARY | |||
|
TN585Y92BI
Created by
admin on Sat Dec 16 08:35:54 GMT 2023 , Edited by admin on Sat Dec 16 08:35:54 GMT 2023
|
PRIMARY | |||
|
m11539
Created by
admin on Sat Dec 16 08:35:54 GMT 2023 , Edited by admin on Sat Dec 16 08:35:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
149193-61-3
Created by
admin on Sat Dec 16 08:35:54 GMT 2023 , Edited by admin on Sat Dec 16 08:35:54 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
